Sosei UK Subsidiary Starts Phase IIb Clinical Trial of AD 452, Investigational Drug for Treating Rheumatoid Arthritis.Tokyo, Japan, Sept 6, 2005 - (JCNN JCNN Japan Corporate News Network ) - Sosei, a Japanese biopharmaceutical company, announced on September 5 that its wholly owned UK subsidiary Arakis has started a phase IIb dose-ranging study of AD 452, an investigational drug for the treatment of rheumatoid arthritis rheumatoid arthritis Chronic, progressive autoimmune disease causing connective-tissue inflammation, mostly in synovial joints. It can occur at any age, is more common in women, and has an unpredictable course. (RA). AD 452 is a low-molecular disease modifying anti-rheumatic drug (DMARD Disease Modifying Anti-Rheumatic Drugs (DMARDs) A class of antirheumatic drugs, including chloroquine, methotrexate, cyclosporine, and gold compounds, that influence the disease process itself and do not only treat its symptoms. Mentioned in: Antirheumatic Drugs ) that is expected to reduce joint inflammation, destruction and pain while preserving mobility. Arakis completed a phase IIa clinical trial of AD 452 in April and obtained positive results. It is estimated that there are about 6 million people with RA in Europe, the US and Japan. The global market for RA drugs is presently estimated at 600 billion yen ($5.5 bil), and is expected to exceed 1 trillion yen ($10.5 bil) in 2008. Source: JCN JCN Japan Corporate News JCN Journal of Cognitive Neuroscience JCN Journal of Cardiovascular Nursing JCN Journal of Christian Nursing JCN Job Control Number JCN Journal of Child Neurology JCN joint communications network (US DoD) http://www.japancorp.net Copyright [c] 2005 Japan Corporate News Network. All rights reserved. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion